US FDA draft guideline seeks to foster drug development for chronic fatigue syndrome
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has released a draft guidance to help drug sponsors develop treatments for chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), a condition for which there are currently no FDA-approved medicines1,2.
You may also be interested in...
Hemispherx 'Redoubling' US Efforts On Ampligen
Chronic fatigue drug received two FDA complete response letters, but company now agrees to additional study, new CEO says. Firm hopes Argentine approval also bodes well.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.